Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis

Wed Feb 28 22:21:15 2024

(2022) The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis. Yale Journal of Biology and Medicine. pp. 495-506. ISSN 0044-0086

Full text not available from this repository.

Official URL: <Go to ISI>://WOS:000905320100008

Abstract

Background: Antibiotic resistance in cystic fibrosis (CF) is a well-known phenomenon. However, the comprehensive epidemiological impact of antibiotic resistance in CF is not clearly documented. So, this meta-analysis evaluated the proportion rates of carbapenem resistance (imipenem, meropenem, and doripenem) in CF based on publication date (1979-2000, 2001-2010, and 2011-2021), continents, pathogens, and antimicrobial susceptibility testing (AST). Methods: We searched studies in PubMed, Scopus, and Web of Science (until April 2021). Statistical analyses were conducted using STATA software (version 14.0). Results: The 110 studies included in the analysis were performed in 25 countries and investigated 13,324 pathogens associated with CF. The overall proportion of imipenem, meropenem, and doripenem resistance in CF were 43 (95 CI 36-49), 48 (95 CI 40-57), 28 (95 CI 23-33), and 45 (95 CI 32-59), respectively. Our meta-analysis showed that trends of imipenem, meropenem, and doripenem-resistance had gradual decreases over time (1979-2021). This could be due to the limited clinical effectiveness of these antibiotics to treat CF cases over time. Among the opportunistic pathogens associated with CF, the highest carbapenem resistance rates were shown in Stenotrophomonas maltophilia, Burkholderia spp., Pseudomonas aeruginosa, and Staphylococcus aureus. The highest and lowest carbapenem resistance rates among P. aeruginosa in CF patients were shown against meropenem (23) and doripenem (39). Conclusions: We showed that trends of carbapenem resistance had decreased over time (1979-2021). This could be due to the limited clinical effectiveness of these antibiotics to treat CF cases over time. Plans should be directed to fight biofilm-associated infections and prevent the emergence of mutational resistance. Systematic surveillance for carbapenemase-producing pathogens in CF by molecular surveillance is necessitated.

Item Type: Article
Creators:
CreatorsEmail
Saadh, M. J.UNSPECIFIED
Lohrasbi, A.UNSPECIFIED
Ghasemian, E.UNSPECIFIED
Hashemian, M.UNSPECIFIED
Etemad, A.UNSPECIFIED
Dargahi, Z.UNSPECIFIED
Kaviar, V. H.UNSPECIFIED
Keywords: cystic fibrosis antimicrobial resistance carbapenem resistance bacterial pathogens systematic review and meta-analysis burkholderia-cepacia-complex gram-negative bacteria in-vitro activity pseudomonas-aeruginosa antimicrobial susceptibility stenotrophomonas-maltophilia molecular epidemiology antibiotic-resistance achromobacter-xylosoxidans mycobacterium-abscessus Life Sciences & Biomedicine - Other Topics General & Internal Medicine Research & Experimental Medicine
Divisions:
Page Range: pp. 495-506
Journal or Publication Title: Yale Journal of Biology and Medicine
Journal Index: ISI
Volume: 95
Number: 4
ISSN: 0044-0086
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4196

Actions (login required)

View Item View Item